Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.

Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies. Nearly all anticancer drugs presently available to clinicians kill tumor cells by activating an endogenous biochemical pathway for cell suicide, known as programmed cell death or apoptosis. However, many malignant cells develop defects in the regulation of genes that control apoptosis, rendering them resistant to the induction of apoptosis by a wide variety of stimuli, including chemotherapeutic drugs and radiotherapy. The BCL-2 family of proto-oncogenes are critical regulators of apoptosis whose expression frequently becomes altered in human cancers, including some of the most common types of lymphomas and leukemias. The first member of this gene family to be identified was BCL-2, by virtue of its involvement in t(14;18) chromosomal translocations commonly found in B-cell non-Hodgkin's lymphoma (NHL). Subsequently, however, overexpression of Bcl-2 has been reported in a wide variety of cancers, without associated chromosomal translocations. A variety of experiments have provided conclusive evidence that elevations in Bcl-2 expression cause resistance to chemotherapeutic drugs, while decreases in Bcl-2 expression promote apoptotic responses to anticancer drugs. Information about the biochemical mechanisms of action of the Bcl-2 protein and other members of the Bcl-2 family is beginning to suggest strategies for overcoming the cytoprotective effects of Bcl-2 overexpression in lymphomas, leukemias, and other types of cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Seminars in hematology Pubmed

Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.

Seminars in hematology , Volume 34 (4 Suppl 5): 11 – Jan 20, 1998

Bcl-2 family proteins: regulators of apoptosis and chemoresistance in hematologic malignancies.


Abstract

Nearly all anticancer drugs presently available to clinicians kill tumor cells by activating an endogenous biochemical pathway for cell suicide, known as programmed cell death or apoptosis. However, many malignant cells develop defects in the regulation of genes that control apoptosis, rendering them resistant to the induction of apoptosis by a wide variety of stimuli, including chemotherapeutic drugs and radiotherapy. The BCL-2 family of proto-oncogenes are critical regulators of apoptosis whose expression frequently becomes altered in human cancers, including some of the most common types of lymphomas and leukemias. The first member of this gene family to be identified was BCL-2, by virtue of its involvement in t(14;18) chromosomal translocations commonly found in B-cell non-Hodgkin's lymphoma (NHL). Subsequently, however, overexpression of Bcl-2 has been reported in a wide variety of cancers, without associated chromosomal translocations. A variety of experiments have provided conclusive evidence that elevations in Bcl-2 expression cause resistance to chemotherapeutic drugs, while decreases in Bcl-2 expression promote apoptotic responses to anticancer drugs. Information about the biochemical mechanisms of action of the Bcl-2 protein and other members of the Bcl-2 family is beginning to suggest strategies for overcoming the cytoprotective effects of Bcl-2 overexpression in lymphomas, leukemias, and other types of cancer.

Loading next page...
 
/lp/pubmed/bcl-2-family-proteins-regulators-of-apoptosis-and-chemoresistance-in-OGLOcixIKA

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
0037-1963
pmid
9408956

Abstract

Nearly all anticancer drugs presently available to clinicians kill tumor cells by activating an endogenous biochemical pathway for cell suicide, known as programmed cell death or apoptosis. However, many malignant cells develop defects in the regulation of genes that control apoptosis, rendering them resistant to the induction of apoptosis by a wide variety of stimuli, including chemotherapeutic drugs and radiotherapy. The BCL-2 family of proto-oncogenes are critical regulators of apoptosis whose expression frequently becomes altered in human cancers, including some of the most common types of lymphomas and leukemias. The first member of this gene family to be identified was BCL-2, by virtue of its involvement in t(14;18) chromosomal translocations commonly found in B-cell non-Hodgkin's lymphoma (NHL). Subsequently, however, overexpression of Bcl-2 has been reported in a wide variety of cancers, without associated chromosomal translocations. A variety of experiments have provided conclusive evidence that elevations in Bcl-2 expression cause resistance to chemotherapeutic drugs, while decreases in Bcl-2 expression promote apoptotic responses to anticancer drugs. Information about the biochemical mechanisms of action of the Bcl-2 protein and other members of the Bcl-2 family is beginning to suggest strategies for overcoming the cytoprotective effects of Bcl-2 overexpression in lymphomas, leukemias, and other types of cancer.

Journal

Seminars in hematologyPubmed

Published: Jan 20, 1998

There are no references for this article.